Dr. Sudarshan Sharma, MD
Claim this profileSudarshan K Sharma MD Limited-Gynecologic Oncology
About Sudarshan Sharma, MD
Education:
- Graduated from Punjab State Medical Faculty, India, in 1972.
- Completed Residency in Obstetrics & Gynecology at Loyola University Medical Center (1977-1981).
- Undertook a Fellowship in Gynecologic Oncology at Loyola University Medical Center (1984-1986).
Experience:
- Board certified in Gynecologic Oncology and Obstetrics & Gynecology.
- Practicing since 1986, with a specialization in minimally invasive surgery using the da Vinci Robot.
Area of expertise
Ovarian Cancer
Sudarshan Sharma, MD has run 9 trials for Ovarian Cancer. Some of their research focus areas include:
Fallopian Tube Cancer
Sudarshan Sharma, MD has run 6 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Affiliated Hospitals
Sudarshan K Sharma MD Limited-Gynecologic Oncology
Sudarshan K Sharma MD Limted-Gynecologic Oncology
Clinical Trials Sudarshan Sharma, MD is currently running
Navtemadlin
for Endometrial Cancer
This trial tests navtemadlin to see if it can prevent endometrial cancer from returning in patients who responded well to chemotherapy. The study will check the safety and effectiveness of different doses of the drug.
Recruiting
0 awards
Phase 2 & 3
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Sudarshan Sharma, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Sudarshan Sharma, MD has experience with
- Quality-of-Life Assessment
- Questionnaire Administration
- Olaparib
- Cediranib Maleate
- Durvalumab
- Carboplatin
Breakdown of trials Sudarshan Sharma, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Ovarian Carcinoma
Peritoneal Serous Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sudarshan Sharma, MD specialize in?
Sudarshan Sharma, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage IV.
Is Sudarshan Sharma, MD currently recruiting for clinical trials?
Yes, Sudarshan Sharma, MD is currently recruiting for 3 clinical trials in Hinsdale Illinois. If you're interested in participating, you should apply.
Are there any treatments that Sudarshan Sharma, MD has studied deeply?
Yes, Sudarshan Sharma, MD has studied treatments such as Quality-of-Life Assessment, Questionnaire Administration, Olaparib.
What is the best way to schedule an appointment with Sudarshan Sharma, MD?
Apply for one of the trials that Sudarshan Sharma, MD is conducting.
What is the office address of Sudarshan Sharma, MD?
The office of Sudarshan Sharma, MD is located at: Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois 60521 United States. This is the address for their practice at the Sudarshan K Sharma MD Limited-Gynecologic Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.